This report was first published by Endpoints News. To see the original version, click here
BOSTON — Greetings from Boston, where I’ve been on the ground covering the American Society of Gene & Cell Therapy’s annual meeting all week.
It’s a crucial moment for the field. Genetic medicine developers haven’t recovered from biotech’s funding doldrums. Many approved gene therapies have been commercial flops, causing companies to increasingly abandon rare disease research. Federal funding, vital to academic research, is still in limbo. The FDA is in turmoil.
您已阅读7%（555字），剩余93%（7032字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。